ADVM — Adverum Biotechnologies Share News
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
U.S. RESEARCH ROUNDUP- Entegris, FedEx, Kellogg
Brief: Adverum Biotechnologies Receives Nasdaq Notice On Regained Compliance With Minimum Bid Price Requirement
Brief: Adverum Grants License To Ray Therapeutics For AAV.7m8 Intravitreal Capsid
Brief: Adverum Biotechnologies- On May 18, Received Approval From Nasdaq To Transfer Listing Of Co's Common Stock Nasdaq Capital Market
Brief: Adverum Biotechnologies Introduces An Intravitreal Gene Therapy Program For Geographic Atrophy And Presents Data On Its Ocular Gene Therapy Platform
Adverum Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Adverum Biotechnologies Reports First Quarter 2023 Financial Results
Adverum Biotechnologies Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Adverum Biotechnologies Inc Files For Mixed Shelf Of Up To $300 Mln – SEC Filing
Brief: Adverum Biotechnologies Granted Innovative Licensing In The UK For Ixo-Vec For The Treatment Of Wet AMD
Brief: Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Its Gene Therapy
Adverum Biotechnologies Inc reports results for the quarter ended in December - Earnings Summary
Brief: Adverum Biotechnologies Inc Reports Quarterly Loss Per Share Of $0.33
Adverum Biotechnologies Inc expected to post a loss of 36 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
Brief: Adverum Biotechnologies Inc Says Linda Rubinstein Appointed CFO
Gene therapy co Adverum falls on Nasdaq delisting notice
Brief: Adverum Biotechnologies Inc - On November 18, Co Received Notice Of Delisting From Nasdaq
U.S. RESEARCH ROUNDUP-Expensify, NVIDIA, Signature Bank